A bad year to be an American medtech
Big-cap device makers on European exchanges did nicely in 2021, whereas their US-listed brethren had a harder time.
Role reversal for large-cap medtechs
Shareholders are rewarding the kinds of companies they punished a year ago.
Venture-backed medtechs rush for the exit
A lot of money is sloshing around, and medical device start-ups are reaping the benefits.
Onduo takes its time
The Verily subsidiary has the luxury of patient backers. But hungrier rivals could steal a march.
Medtech deal-making stands firm in difficult times
It takes more than a pandemic to stop medical device companies merging.
Telemedicine and the “Zoom effect” boost big-cap medtech
In the second half of 2020 medtech began a tentative – and possibly short-lived – recovery.
Teladoc bets $18.5bn that Covid-19 will change the world for good
The purchase of Livongo is the richest healthcare deal this year, but questions about reimbursement, competition and profitability remain.
